Combinations of hormones and local therapies in locally advanced prostate carcinoma

ONCOLOGY

Volumn 10, Issue 8, 1996, Pages 1193-1202

  Eulau, Stephen M ^a   Corn, Benjamin W ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GOSERELIN; HORMONE; LEUPRORELIN; MEGESTROL; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; APOPTOSIS; BIOPSY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MALE; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

ANDROGEN ANTAGONISTS; APOPTOSIS; BIOPSY; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS;

EID: 0029794822     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA 45:8-30, 1995.
2. Kramer S: Patterns of care study: A nationwide evaluation of the practice of radiation therapy in Cancer management. Int J Rad Oncol Biol Phys 1-1231-36, 1976.
3. Hanks GE: External beam radiation for prostate Cancer: Patterns of care study in the United States. NCI Monogr 7:85-94, 1988.
4. Perez CA, Pilepich MW, Garcia D, et al: Definitive radiation therapy in carcinoma of the prostate, localized to pelvis: Experience at Mallinkrodt Institute of Radiology. NCI Monogr 7:85-94, 1988.
5. Scott RJ, Mutchnik DL, Laskowski TZ, et al: Carcinoma of the prostate in elderly men: Incidence, growth characteristics and clinical significance. J Urol 101-602-607. 1969.
6. Belt E, Schroeder FH: Total perineal prostatectomy for carcinoma of the prostate. J Urol 107:91-96, 1972.
7. Schroeder FH, Belt E: Carcinoma of the prostate: A study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol 114: 257-261, 1975.
8. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic cancer of the prostate Cancer Res 1:293-297, 1941.
9. Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7:165-170, 1988.
10. Labrie F, Belanger A, Dupont A, et al: Science behind total androgen blockade: From gene to combination therapy. Clin Invest Med 16(6):475-492, 1993.
11. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989.
12. Isaacs JT: Antagonist effect of androgen on prostate cell death. Prostate 5:545, 1984.
13. Murphy WM, Soloway MS, Barrows GH: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68:821-828, 1991.
14. Pollack A, Zagars GK, Kopplin S: Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 32(1):13-20, 1995.
15. Hanks GE: Optimizing the radiation treatment and outcome of prostatic Cancer. Int J Radiat Oncol Bio Phys 11:1235-1245, 1985.
16. English HF, Kyprianou N, Isaacs JT Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15:233-250, 1989.
17. Meyn RE, Stephens LC, Ang KK, et al: Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies Int J Radiat Biol Phys 64(5):583-591, 1993.
18. Stephens LC, Hunter NR, Ang KK, et al: Development of apoptosis as a function of time and dose. Radiat Res 135:75-80, 1993.
19. Andriole GL: Serum prostate specific antigen: The most useful tumor marker. J Clin Oncol 10.1205-1207. 1992.
20. Fair WR, Aprikian A, Sogani P, et al: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71(3; suppl):1031-1038, 1993.
21. Young CYF, Montgomery BT, Andrews PE, et al: Hormonal regulation of prostate specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51:3748-3752, 1991.
22. Oesterling JE, Andrews PE, Suman VJ, et al: Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149:779-782, 1993.
23. Bruchovsky N, Rennie PS, Coldman AJ, et al: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50:2275-2282, 1990
24. Bagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate Cancer at Stanford University. NCI Monogr 7:47-60, 1988.
25. Green N, Bodner H, Broth E, et al: Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 10.971-976, 1984.
26. Porter AT, Venner PM: The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer - the Canadian perspective, in The Treatment of Prostatic Cancer: Facts and Controversies, pp 231-237. EORTC Genitourinary Group Monograph 8, 1990.
27. Pilepich MV, Buzydlowski JW, John MJ, et al: Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07. Int J Rad Oncol Biol Phys 32(1):175-180, 1995.
28. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy. Proc Am Soc Clin Oncol 14:239A, 1995.
29. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45(4):616-623, 1995.
30. Modig H, Tomic R, Granfors T, et al: Prospective randomized trial in localized prostatic Cancer: Radiotherapy versus radiotherapy and orchidectomy (abstract 1323). Proc ESTRO, 1993.
31. Zincke H: Bilateral pelvic lymphadenectomy and radical prostatectomy for stage C or D1 adenocarcinoma of the prostate: Possible beneficial effect of adjuvant treatment. NCI Monogr 7:109-115, 1988.
32. 31a. Bolla M, Gonzalez D, Warde P, et al: Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer: Results of a randomized phase III clinical trial of the EORTC radiotherapy and genitourinary tract cancer cooperative groups. ASCO 15:238, 1996.
33. Soffen EM, Marks GE, Hunt MA, et al: Conformal field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity Int J Radiat Oncol Biol Phys 24:485-488, 1992.
34. Zelefsky MJ, Leibel SA, Burman CM, et al: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic Cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29(4):755-761, 1994.
35. Forman JD, Kumar R, Haas G, et al: Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer invest 13(1):8-15, 1995.
36. Boxer RJ, Kauffman JJ, Goodwin WE: Radical prostatectomy for carcinoma of the prostate: A review of 329 cases. J Urol 117:208-218, 1977.
37. Valett BS: Radical perineal prostatectomy subsequent to bilateral orchiectomy. Del Med J 16:18-20, 1994.
38. Sullivan JJ, Hartwig CH: The use of estrogen therapy preliminary to radical perineal prostatectomy. J Urol 70:499-502, 1953.
39. Scott WW, Boyd HL: Combine hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based on 25 years of experience. J Urol 101:86-92, 1969.
40. Zincke H: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 33(5; suppl):27-36, 1989.
41. Corn BW, Hanks GE: Therapeutic options for clinically localized carcinoma of the prostate. Seminars in Radiat Oncol 3(3):187-197, 1993.
42. Lerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary morbidity. J Urol 154:1447-1452, 1995.
43. Narayan P, Lowe BA, Carrol PR, et al. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br J Urol 73:544-548, 1994.
44. Morgan WR, Myers RP: Endocrine therapy prior to radical retropubic prostatectomy for clinical stage C prostate Cancer: Pathologic and biochemical response. J Urol 145:316A, 1991.
45. Soloway MS, Hachiya T, Civantos F, et al: Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate Cancer. Urology 43(2; suppl):52-56, 1994.
46. Andros EA, Dansghari F, Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 16(6):510-515., 1993
47. MacFarlane MT, Abi-Aad A, Stein A, et al: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 150:132-134, 1993.
48. Voges GE, Mottrie AM, Stockle M, et al: Hormone therapy prior to radical prostatectomy in patient with clinical stage C prostate cancer. Prostate 5(suppl):4-8, 1994.
49. Vapnek JM, Carroll PR: Neoadjuvant hormonal downsizing of clinical stage C carcinoma of the prostate. J Urol 147:247A, 1992.
50. Flamm J, Fischer M, Holtl W, et al: Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate. Eur Urol 19:192-195, 1991.
51. Monfette G, Dupont A, Labrie F, et al: Multiple advantages before and after radical prostatectomy with combine endocrine therapy, in Altwein JE, Faul P, Schneider W (eds): Incidental Carcinoma of the Prostate, pp 246-253. New York, Springer, 1991.
52. Fair WR, Aprikian AG, Cohen D, et al: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16(6):516-522, 1993.
53. Fair WR, Wang Y, Cohen D, et al: Neoadjuvant androgen deprivation in patients with clinically localized prostate cancer - Effect on (+) margins and post-operative PSA. J Urol 153:313A, 1995.
54. Solomon MH, McHugh TA, Dorr RP, et al: Hormone ablation as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 16(6):532-538, 1993.
55. Schulman CC: Neoadjuvant androgen blockade prior to prostatectomy: A retrospective study and critical review. Prostate 5(suppl):9-14, 1994.
56. Gomella LG, Liberman SN, Mulholland SG, et al: Induction androgen deprivation plus prostatectomy for stage T3 disease: Failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Urology 47:870-877, 1996.
57. LaBrie F, Cusan L, Gomez JL, et al: Down-staging of early stage prostate Cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a leuteinizing hormone-releasing hormone agonist. Urology Symposium 44(6A):29-37, 1994.
58. Pederson KV, Lundberg S, Hugosson J, et al: Neoadjuvant hormonal treatment with tripterelin versus no treatment prior to radical prostatectomy: A prospective randomized multicenter study J Urol 153:391A, 1995.
59. Soloway MS, Shanfi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate Cancer. J Urol 154:424-428, 1995.
60. Van Poppel, Ridder DD, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. J Urol 154:429-434, 1995.
61. Isaka S, Shimazaki J, Akimoto S, et al: A prospective trial for treating stages B2 and C prostate cancer: Radical surgery or irradiation with neoadjuvant endocrine therapy. Jpn J Clin Oncol 24(4):218-223, 1994.